These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32984034)

  • 21. Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
    Spanheimer PM; Lorenzen AW; De Andrade JP; Kulak MV; Carr JC; Woodfield GW; Sugg SL; Weigel RJ
    Ann Surg Oncol; 2015 Dec; 22(13):4287-94. PubMed ID: 25971960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
    Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
    Tannir NM; Schwab G; Grünwald V
    Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 25. Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy.
    Mirshafiey A; Ghalamfarsa G; Asghari B; Azizi G
    Innov Clin Neurosci; 2014 Jul; 11(7-8):23-36. PubMed ID: 25337443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.
    Rimassa L; Danesi R; Pressiani T; Merle P
    Cancer Treat Rev; 2019 Jul; 77():20-28. PubMed ID: 31195212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.
    Xu H; Shen J; Xiang J; Li H; Li B; Zhang T; Zhang L; Mao X; Jian H; Shu Y
    Cancer Manag Res; 2019; 11():6343-6351. PubMed ID: 31372039
    [No Abstract]   [Full Text] [Related]  

  • 28. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.
    Ye L; Santarpia L; Gagel RF
    Endocr Rev; 2010 Aug; 31(4):578-99. PubMed ID: 20605972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.
    Ruiz-Morales JM; Heng DY
    Ther Adv Urol; 2016 Dec; 8(6):338-347. PubMed ID: 27904650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.
    Klug LR; Kent JD; Heinrich MC
    Pharmacol Ther; 2018 Nov; 191():123-134. PubMed ID: 29964125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.
    Xie L; Xu J; Guo W; Wang Z; Yao Y; Li J; Lin J; Xiao J; Yu X; Zhang W; Cai Z; Hua Y; Chen J; Shao Z; Wu D; Wu S; Tu Z; Zhang X
    Front Oncol; 2021; 11():696865. PubMed ID: 34367981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
    Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
    PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arylurea Derivatives: A Class of Potential Cancer Targeting Agents.
    Chen JN; Wu DW; Li T; Yang KJ; Cheng L; Zhou ZP; Pu SM; Lin WH
    Curr Top Med Chem; 2017 Nov; 17(28):3099-3130. PubMed ID: 28685689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
    Li X; Xu A; Li H; Zhang B; Cao B; Huang J
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1693-1701. PubMed ID: 29486282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come?
    Grünwald V; Merseburger AS
    Eur J Cancer; 2013 Jul; 49(11):2504-11. PubMed ID: 23601669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Zhu VW; Klempner SJ; Ou SI
    Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
    Mody K; Abou-Alfa GK
    Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
    Tolmachev V; Stone-Elander S; Orlova A
    Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.